Switch Subset


DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Observed efficacy in switch subset1,2

DESCOVY FOR PrEP was noninferior to TRUVADA2

Efficacy data in switch subset in the DISCOVER study of DESCOVY® (emtricitabine and tenofovir alafenamide)
  • Primary analysis: when 100% of patients reached Week 48 and ≥50% reached Week 962
  • Patients who switched: Patients who were using TRUVADA at baseline and randomized to DESCOVY FOR PrEP2
  • Patients who continued: Patients using TRUVADA at baseline who continued using the drug2
Renal Data